Exhibit 99.3

EDG Capital, Inc. Announces Assignment and Filing Of Two Provisional U.S. Patent
           Applications for Nine New Radiopharmaceutical Technologies
                          for the Treatment of Cancer.

NEW YORK, July 11, 2001 - EDG Capital, Inc. (OTCBB: EDGN), a developer of
nuclear pharmaceuticals for therapeutic use in the treatment of cancer,
announced that on June 29, 2001, its radiation oncology managed research group,
Center for Molecular Medicine, assigned to EDG's operating subsidiary, Isotope
Solutions Inc. (ISI), two provisional U.S. patent applications for nine new
radiopharmaceutical technologies for the treatment of cancer.

The new provisional patent applications, entitled "Radioactive Platinum
Complexes for Cancer Treatment" and "Radioactive Platinum Complexes for
Treatment of Malignant Tumors," were filed by Wayne S. Court, PhD, MD, Associate
Director of the Center for Molecular Medicine, on June 25, 2001 and assigned to
the Center for Molecular Medicine on June 28, 2001.

EDG is working with its advisors to prepare full utility U.S. patent
applications for these new radiopharmaceutical technologies.

"Our vision is to develop novel radiopharmaceuticals for the treatment of
cancer," said Jack Schwartzberg, Chief Executive Officer, President and Chairman
of EDG. "With the addition of these new radiopharmaceutical technologies, we are
taking a significant step forward toward achieving this goal."

One of EDG's early radiopharmaceuticals, 195mPt-Cisplatin or Radioactive
Cisplatin, was designed to enhance the tumor-killing potential of the
non-radioactive drug that is currently approved and used worldwide. To further
extend the range of therapeutic alternatives, other platinum-based drugs have
been developed and our new pending patent applications seek to cover radioactive
forms of these drugs. The pending applications cover three isotopic forms
(191Pt, 193mPt and 195mPt) of the drugs Carboplatin, Iproplatin and JM216, as
follows:

      1.    191Pt-Carboplatin
      2.    193mPt-Carboplatin
      3.    195mPt-Carboplatin
      4.    191Pt-JM216
      5.    193mPt-JM216
      6.    195mPt-JM216



      7.    191Pt-Iproplatin
      8.    193mPt-Iproplatin
      9.    195mPt-Iproplatin

"Because these platinum-based drugs will be made directly radioactive through
their platinum component," said Mr. Schwartzberg, "we believe that these
products will have the potential to achieve enhanced therapeutic effect with
fewer and more tolerable side effects than their parent platinum-based
compounds. In addition, we hope that these new radiopharmaceuticals will provide
alternative treatments for situations of tumor resistance or intolerance to the
parent platinum-based compounds."

ISI's Radioactive Cisplatin Technology (195mPt-Cisplatin) - Standard cisplatin
is an effective and widely used chemotherapeutic agent for the treatment of
various types of cancers. Cisplatin contains the element platinum and works by
binding with tumor cell DNA, thereby disrupting its reproduction. Radioactive
Cisplatin is chemically identical to standard cisplatin except that the platinum
it contains has been made radioactive. Radioactive Cisplatin is therefore
designed to deliver high-doses of radioactivity directly into the tumor cells,
with the intent of minimizing injury to surrounding tissues and organs.

About EDG Capital, Inc. Through its wholly-owned subsidiary, Isotope Solutions,
Inc., EDG Capital is engaged in the research, development and testing of nuclear
pharmaceuticals for therapeutic use in the treatment of the most lethal forms of
cancer. Internationally renowned clinicians, who are under management contracts
with Isotope Solutions Inc., conduct research for the company.

Legal Disclaimers: This press release may contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results of operations may differ materially from those projected or suggested in
the forward-looking statements. The forward-looking statements contained herein
represent EDG Capital, Inc.'s judgment as of the date of this release, and EDG
Capital, Inc. cautions investors not to place undue reliance on such statements.

CONTACT:    EDG Capital, Inc., New York
            Shragie David Aranoff
            COO, Vice President
            516/222-5154
            shragie@isotopesolutions.com



            Or

            Rubenstein Associates, Inc.
            Patricia Amerman
            Vice President
            212/843-8049
            pamerm@rubenstein.com